This clinical trial is focused on studying a condition known as venous thromboembolism (VTE), which involves the formation of blood clots in the veins. The study is particularly interested in patients who have VTE associated with cancer. Two treatments are being compared in this trial: Abelacimab, a solution for infusion, and Apixaban, a film-coated tablet. Abelacimab is administered through an infusion, which means it is given directly into the bloodstream, while Apixaban is taken orally as a tablet.

The purpose of the study is to evaluate whether Abelacimab is as effective as Apixaban in preventing the recurrence of VTE in patients with cancer over a period of six months. If Abelacimab proves to be at least as effective, the study will further assess if it might be even better. Participants in the study will receive either Abelacimab or Apixaban and will be monitored for any recurrence of VTE and any bleeding events during the six-month period.

This trial is designed to provide valuable information on the effectiveness and safety of these treatments for patients with cancer-related VTE. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered, but the evaluation of the results is blinded to ensure unbiased assessment. The trial aims to help improve treatment options for patients dealing with this serious condition.